EcoSynthetix reported a small per-share loss for the third quarter. Supplemental headlines point to a sharp drop in sales from a year earlier and adjusted EBITDA close to break-even.
EcoSynthetix Inc. (TSX: ECO) released its results after the market closed on November 3, 2026, for the quarter ended September 30. The earnings calendar lists EPS of -C$0.0062 but gives no estimate for the quarter, so there’s no basis for calling it a beat or miss. Unverified headlines report sales of US$3.6 million, down 38% year over year, and adjusted EBITDA of about US$39,000. For more coverage, visit the ECO.TO stock page.
Recent earnings trend
EcoSynthetix Inc
ECO.TO
ECO.TO
EcoSynthetix Inc
WealthAwesomeMarket cap
$94.64M
52W high
$5.02
52W low
$1.26
1W change
+16.67%
Beta
0.58
Analyst Price Targets
Based on analyst covering ECO · as of Sep 17, 2026
Wall Street analysts forecast ECO stock price to rise 421.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$8.39
+421.1% Upside
Current Price
C$1.61
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ECO's historical volatility
30-Day Vol
88.3%
Annualized
90-Day Vol
70.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.52 | C$1.12 – C$2.06 |
| 60 trading days | C$1.43 | C$0.93 – C$2.20 |
| 90 trading days | C$1.35 | C$0.79 – C$2.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-03 | -0.0062 | — | — |
| 2026-06-30 | 2026-07-28 | -0.0101 | — | — |
| 2026-03-31 | 2026-05-07 | -0.0138 | — | — |
| 2025-12-31 | 2026-02-19 | 0.0036 | — | — |
| 2025-09-30 | 2025-11-06 | -0.0021 | — | — |
| 2025-06-30 | 2025-07-29 | 0.0026 | — | — |
Investor takeaway: The calendar shows a small loss per share, but no matching estimate. The reported sales decline is the more significant signal, while adjusted EBITDA was reportedly close to break-even. A new account with a global top-five tissue producer could support growth, but the available headline doesn’t say how much revenue it may bring or when. The reported US$29.4 million in cash and term deposits also needs to be checked against company filings. With few analysts covering the stock, separate company-reported results from limited consensus data.
Sales reportedly fell 38% year over year
Supplemental headlines put Q3 sales at US$3.6 million, down 38% from a year earlier. The earnings calendar lists EPS of -C$0.0062 but no estimate, so it doesn’t support an actual-versus-consensus comparison. Check the sales and adjusted EBITDA figures against EcoSynthetix’s official results before drawing conclusions.
Bull case
The reported account with a global top-five tissue producer could help EcoSynthetix add to its customer base. If confirmed in the company’s release, adjusted EBITDA of about US$39,000 would put the quarter near operating break-even despite the reported sales decline. The reported US$29.4 million in cash and term deposits could also give the company financial flexibility. Check the official statements for its full cash position, cash use and outlook.
Bear case
The reported 38% year-over-year sales decline is a serious concern. The new account doesn’t yet show that the company has replaced the lost or lower sales. The calendar lists negative EPS, and the fundamentals snapshot shows negative trailing EPS and a -4.79% profit margin.
Next-quarter consensus comes from one analyst and estimates EPS of -C$0.01 and revenue of $4.14 million, with revenue growth of -7.4%. That’s a limited and uncertain benchmark, not a broad market view. The share price is also below its 50- and 200-day moving averages.
Analysis
For the quarter ended September 30, EcoSynthetix’s earnings-calendar entry lists actual EPS of -C$0.0062 but no estimate. Investors shouldn’t treat the result as a beat or miss. For the next quarter, one analyst estimates EPS of -C$0.01 and revenue of $4.14 million, with revenue growth of -7.4%. With so few analysts covering the stock, these figures offer only a limited reference point. The automatically added earnings trend table and chart show historical results, but they don’t replace the company’s full quarterly statements.
Analysis
Unverified supplemental headlines report Q3 sales of US$3.6 million, down 38% year over year, and adjusted EBITDA of about US$39,000. They also mention a new account with a global top-five tissue producer. The account could matter over time, but the available information doesn’t say how much it may contribute or when sales could begin.
The same headlines cite US$29.4 million in cash and term deposits. Before assessing the company’s financial runway, check these figures, cash flow and management’s outlook in the official release and filings. For company-specific coverage and data, visit the ECO.TO overview.
Analysis
Available analyst-target data shows an average target of C$8.39, compared with a last close of C$1.61—a difference of 421.1%. The bullish label reflects that gap; a formal rating isn’t available for this Canadian listing. With limited analyst coverage, don’t treat the target as a reliable expected return. See the analyst price-target details.
Wealth Awesome’s statistical 90-day price model is not financial advice. It gives a mean forecast of C$1.35, with a 68% range of C$0.79 to C$2.28 and a 95% range of C$0.47 to C$3.87. The model also shows annualized drift of -50.0% and 30-day volatility of 88.3%. These are model estimates, not company guidance or guarantees. Review the price forecast details.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
